Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure
Results from the 17,000-patient cardiovascular outcomes trial for dapagliflozin, the sodium glucose co-transporter 2 (SGLT2) inhibitor sold as Farxiga (AstraZeneca), presented today at the American Heart Association (AHA) annual meeting in Chicago show the type 2 diabetes (T2D) drug safely controls blood glucose, significantly reduces hospitalization for heart failure, and may slow the loss of kidney function. The drug did not produce the same mortality benefits seen with competitors in the class.
The big news, however, is what heart failure specialists have wondered about for some time—dapagliflozin, and perhaps the entire SGLT2 class, might someday be used to prevent heart failure among a much larger group of T2D patients who are at risk but have not become seriously ill. In the United States, 30 million people have diabetes; all but 1.25 million have T2D. About 5.7 million people have heart failure, and diabetes is a leading cause. About half of those with heart failure die within 5 years of diagnosis.
“The SGLT2 inhibitor benefits for heart failure and renal dysfunction were quite consistent for all populations of patients, with or without pre-existing atherosclerotic cardiovascular disease (ASCVD),” and with and without pre-existing heart failure or kidney disease, said lead study author Stephen D. Wiviott, MD, FACC, of Brigham and Women’s Hospital, in an interview with The American Journal of Managed Care®
). The study published simultaneously in the New England Journal of Medicine.1
Previous cardiovascular outcomes trials for the SGLT2 inhibitors empagliflozin (Jardiance, Eli Lilly/Boehringer Ingelheim) and canagliflozin (Invokana, Janssen) prompted the American Diabetes Association and the European Society of Cardiology to revise guidelines for patients with known cardiovascular disease. DECLARE-TIMI 58 presented in Chicago at the American Heart Association annual meeting, was designed differently from those trials and included more than 10,000 patients who had risk factors for ASCVD but had not developed the disease.
The results offer the strongest evidence to date that treating healthier T2D patients with SGLT2 inhibitors can prevent heart failure among those at risk for this condition, a finding that could have enormous impact on managed care. The Framingham Heart Study
has found that women with diabetes are 5 times more likely to develop heart failure, and men 2.4 times more likely to develop it. Patients with heart failure are among the sickest in the health system, with total costs of $30 billion a year, according to the CDC.
“These new data suggest that in patients without established atherosclerotic cardiovascular disease, SGLT2 inhibition can prevent serious clinical events, particularly hospitalization for heart failure, and possibly reduce the likelihood of progression of renal disease,” the authors wrote in their findings.
A meta-analysis of the 3 major cardiovascular outcomes trials involving SGLT2 inhibitors, appearing in The Lancet
appearing less than an hour after presentation of the DECLARE-TIMI 58 results, found that drugs in this class appear to be producing modest results in reducing heart attacks and strokes, but "robust" outcomes in reducing hospitalization for heart failure and progression of renal disease.2
Under a 2008 FDA guidance, makers of all T2D therapies were required to conduct large cardiovascular outcomes trials to ensure that the drugs did not cause heart attacks, strokes, or early cardiovascular death. The diabetes community was stunned in September 2015 when results from EMPA-REG OUTCOME
showed that empagliflozin was not only safe, but also produced a 38% reduction in cardiovascular deaths and a 32% reduction in deaths from any cause, in addition to a 35% reduction in hospitalization for heart failure.
Canagliflozin followed in June 2017 with results from CANVAS
, which found a 14% reduction in a composite outcome of reduction in death from cardiovascular causes, myocardial infarction, and stroke, but an increased risk of lower extremity amputation. The CANVAS results also showed a delay in loss of renal function and a reduction in hospitalization for heart failure; while the reduction was greater for those with established heart failure (39% vs 13%), CANVAS also hinted at a protective benefit
that should be confirmed in other trials.
After the EMPA-REG OUTCOME results were announced, the DECLARE-TIMI 58 investigators decided to include 2 primary efficacy outcomes: (1) major adverse cardiovascular events, or MACE; and (2) a composite of cardiovascular death and hospitalization for heart failure. AstraZeneca had previously announced topline results for DECLARE-TIMI 58. Complete results of 17,160 patients who were followed for a median of 4.2 years found:
- Dapagliflozin was noninferior to placebo with respect to the primary safety outcome (95% CI, <1.3; P <.001 for noninferiority).
- For the first primary efficacy endpoint, dapagliflozin did not result in a lower rate of MACE (8.8% for the MACE group vs 9.4% in the placebo group; hazard ratio [HR], 0.93; 95% CI, 0.84 to 1.03; P = .017).
- For the second primary efficacy endpoint, dapagliflozin did result in a lower composite rate of cardiovascular death and hospitalization for heart failure, or HHF (4.9% vs 5.8% for placebo), for a reduction of 17%. This was driven by the reduction in HHF (composite HR 0.83; 95% CI, 0.73 to 0.95; P = .005); there was no between group differences in cardiovascular death. The HR for HHF was 0.73; 95% CI, 0.61 to 0.88).
The study authors say that while they cannot rule out that differences between the drugs themselves account for the lack of a mortality benefit in DECLARE-TIMI 58, they speculated that trial design may account for this, given the drug’s mechanism of action. They note the trial had a “a more restrictive exclusion of patients according to creatinine clearance,” that could account for the difference; mortality rates were lower in the placebo group than in EMPA-REG OUTCOME, suggesting population differences.
SGLT2 inhibitors have a mechanism of action that involves blocking a protein that normally allows the body to reabsorb glucose; instead, the body discharges excess glucose through the urine, offering people with T2D glycemic control, as well as reduced blood pressure and modest weight loss. Wiviott said in the interview that besides the renal benefits, DECLARE-TIMI 58 showed no evidence of early concerns about bladder cancer—in fact, the treatment group had lower rates.
"These results are clinically relevant to the 425 million people worldwide living with diabetes, of whom those with with type 2 diabetes have a 2-to-5 times greater risk of heart failure with an increased risk of a heart attack or stroke. Heart failure survival rates are ony 50% after 5 years, which is why these new findings are so important in broadening our understanding of how to go beyond blood glucose so we may better address this serious and often overlooked cardiovascular complication," said Elizabeth Bjork, vice president, head of Cardiovascular, Renal and Metabolism, Global Medicines, Development for AstraZeneca, in a statement.
FDA recently held a 2-day hearing on the future of the cardiovascular outcomes trials, which generated the unexpected results in EMPA-REG OUTCOME and have produced the consistent results suggesting a new way forward to prevent heart failure. Asked to reflect on the value of these trials, Wiviott said based the changes to clinical guidelines the trials have already produced, it would be hard to imagine a major new class of diabetes drugs reaching the market without demonstrating cardiovascular benefits.
“It will be sorted out by the clinical community and by the market, in a sense,” he said. “One of my take-home messages about this whole area and what’s happening is that we are really moving to a place where it’s not enough to lower blood sugar—it’s how
you lower it—by choosing the right agents as opposed to simply getting to a specific hemoglobin A1C target.”
Asked about the managed care benefits of using SGLT2 inhibitors and dapagliflozin, in particular, to prevent heart failure, Wiviott said that cost-benefit analyses are still needed. But with an aging population and the prospect for more patients with diabetes and congestive heart failure, there’s no question it’s important to find ways to reduce the long-term costs of these conditions.
“The concept of preventing events does have some real economic merit,” he said. “Most of the heart failure drugs we use are for treating patients with established heart failure.” Preventing heart failure in patients who don’t realize they are at risk for the disease would be a different concept, Wiviott said.
But it’s one that some heart failure specialists almost from the start of the cardiovascular outcomes trials a decade ago, when they argued that FDA should be equally focused on heart failure and not just on events like heart attacks and strokes. In an interview
last year, Brigham and Women’s Eldrin F. Lewis, MD, MPH, said that with diabetes being the number 2 risk factor for heart disease, it’s essential to find ways to prevent heart failure in the T2D population.
“Especially in patients who have what I call the trifecta—hypertension, diabetes, and preexisting atherosclerotic cardiovascular disease—those are very high-risk populations,” he said in the interview. “Lipid lowering is important, as well, in these patients, but we need some type of precision medicine approach to managing the prevention of heart failure.”
1. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes [published November 10, 2018]. N Engl J Med
2. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published online November 10, 2018]. Lancet
. 2018; http://dx.doi.org/10.1016/S0140-6736(18)32590-X.